As expected, MYBL2 was mostly upregulated in cancers such as triple negative breast cancer, bladder urothelial carcinoma stages 2 and 4, and lung adenocarcinoma stages 2 and 4, while SCARA5 was downregulated in cancers such as bladder urothelial carcinoma stages 2 and 4; thyroid carcinoma stage 1, and rectum adenocarcinoma stage 2A (Figure 2). Here, MYBL2 is linked to rectum adenocarcinoma.